June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

Aadi's ABI-009 leads to 42% ORR in rare sarcoma
Aadi Bioscience Inc. (Pacific Palisades, Calif.) reported at ASCO Monday that nab-sirolimus (ABI-009) led to a confirmed investigator-assessed objective response rate of 42%, all partial responses, among 31 evaluable patients with advanced malignant perivascular epithelioid cell tumors in the pivotal Phase II AMPECT trial. Aadi plans to submit an NDA to FDA in late 2019 or early 2020.

Novartis NSCLC data for c-MET inhibitor
Novartis AG (NYSE:NVS; SIX:NOVN) reported data from 97 adult patients with locally advanced or metastatic non-small cell lung cancer harboring c-MET exon 14 skipping mutations in the Phase II GEOMETRY mono-1 trial showing that capmatinib led to a blinded independent review committee-assessed ORR of 68% among treatment-naïve patients (n=28) and 41% among previously treated patients (n=69). The rate of grade 4 adverse events with capmatinib was 4.5%. Novartis, which has rights to the c-Met receptor tyrosine kinase (c-MET; MET; HGFR) inhibitor from Incyte Corp. (NASDAQ:INCY), plans to submit an NDA to FDA this year for capmatinib to treat advanced NSCLC harboring a c-MET mutation. ...